Harpoon Therapeutics Has Dosed The First Patients With Small Cell Lung Cancer In An Ongoing Phase 1/2 Trial Of HPN328 In Combination With Roche's Atezolizumab (Tecentriq)
Portfolio Pulse from Benzinga Newsdesk
Harpoon Therapeutics has begun dosing patients with small cell lung cancer in a Phase 1/2 trial of HPN328 in combination with Roche's Atezolizumab (Tecentriq).
September 15, 2023 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harpoon Therapeutics has started a new phase of clinical trials, which could potentially impact its stock positively if the trials show promising results.
Clinical trials are a significant part of a biotech company's operations. Positive results can lead to regulatory approval and potential revenue, which can positively impact the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Roche's drug Atezolizumab is being used in combination with Harpoon's HPN328 in a clinical trial, which could potentially increase its usage and sales if the trial is successful.
The use of Roche's drug in combination with Harpoon's in a clinical trial could potentially increase its usage and sales if the trial is successful, which could positively impact Roche's stock price.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 75